CDK4 and cancer: While pan-CDK inhibitors were leaving the clinical stage, a new group of CDK inhibitors, specifically targeting CDK4 and CDK6 (hereafter CDK6/6), began to reshape the clinical practice, particularly for certain cancer types.577,627,628 The breakthrough in CDK inhibitor development came with achieving high specificity for CDK4/6.